The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis

Neurology

Volumn 51, Issue 5, 1998, Pages 1342-1352

  Noseworthy, John H ^a   O'Brien, P ^a   Erickson, B J ^a   Lee, D ^a   Sneve, D ^a   Ebers, G C ^a   Rice, G P A ^a   Auty, A ^a   Hader, W J ^a   Kirk, A ^a   Duquette, P ^a   Carter, J ^a   Francis, G ^a   Metz, L ^a   Shuster, E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT OUTCOME;

EID: 0031744008     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.5.1342     Document Type: Article

References (40)

1. Wiebe S, Lee DH, Karlik SJ, et al. Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol 1992;32:643-650.
2. Summer RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: result of drug treatment. Gastroenterology 1979;77(part 2):847-869.
3. Peppercorn MA. Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med 1984;101:377-386.
4. Friedman G. Sulfasalazine and new analogues. Am J Gastroenterol 1986;81:141-144.
5. Pullar T, Hunter JA, Capell HA. Sulfasalazine in rheumatoid arthritis: a double blind comparison of sulfasalazine with placebo and sodium aurothiomalate. BMJ 1983;287:1102-1104.
6. Pinals RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 1986;29:1427-1434. Erratum. Arthritis Rheum 1987;30(4):459.
7. Situnayake RD, Grindulis KA, McConkey B. Long-term treatment of rheumatoid arthritis with sulfasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987;46:177-183.
8. Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988;31:702-713.
9. van der Heijde DM, van Riel PL, Nover-Zwart IH, Gribnau FW, van De Putte LB. Effects of hydroxychloroquine and sulfasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1(8646):1036-1038.
10. Nuver-Zwart IH, van Riel PL, van de Pul, Gribnau FW. A double-blind comparative study of sulfasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulfasalazine. Ann Rheum Dis 1989;48:389-395.
11. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix Davies D, Bacon PA. Treatment of psoriatic arthritis with sulfasalazine: a one-year open study. Clin Rheumatol 1988;7:372-377.
12. Fraser S, Capell HA, Hunter JA, Hopkins R, Bird HA. Sulphasalazine in psoriatic arthritis. Br J Rheumatol 1988;27:49. Abstract.
13. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. BMJ 1986;293:911-914.
14. Feltelius N, Hallgren R. Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 1986;45:396-399.
15. Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988;31:1111-1116.
16. Trnavsky K, Peliskova Z, Vacha J. Sulphasalazine in the treatment of reactive arthritis. Scand J Rheumatol Suppl 1987;67:76-79.
17. Prosiegel M, Neu I, Ruhenstroth Bauer G, et al. Suppression of experimental autoimmune encephalitis by sulfasalazine. N Engl J Med 1989;321:545-546. Letter.
18. Prosiegel M, Neu I, Vogl S, Hoffmann G, Wildfeuer A, Ruhenstroth Bauer G. Suppression of experimental autoimmune encephalomyelitis by sulfasalazine. Acta Neurol Scand 1990;81:237-238.
19. Hoult JR. Pharmacological and biochemical actions of sulphasalazine. Drugs 1986;32:18-26.
20. Ahnfelt-Ronne I, Nielsen OH. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents Actions 1987;21:191-194.
21. Peppercorn MA. Sulfasalazine and related new drugs. J Clin Pharmacol 1987;27:260-266.
22. Comer SS, Jasin HE. In vitro immunomodulatory effects of sulfasalazine and its metabolites. J Rheumatol 1988;15:580-586.
23. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
24. The IFBN Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
25. Paty DW, Li DKB, The University of British Columbia MS/ MRI Analysis Group, The IFBN Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
26. The IFBN Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
27. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
28. Rudick R, Goodkin D, Jacobs L, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-363.
29. Simon J, Jacobs L, Campion M, et al. Magnetic resonance studies of intramuscular interferon b-1a for relapsing multiple sclerosis. Neurology 1998;43:79-87.
30. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group [see comments]. Neurology 1995;45:1268-1276.
31. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of galtiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-708.
32. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
33. Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology 1992;42:859-863.
34. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
35. Mitchell JR, Karlik SJ, Lee DH, Fenster A. Computer-assisted identification and quantification of multiple sclerosis lesions in MR imaging volumes in the brain. J Magn Reson Imaging 1994;4:197-208.
36. O'Brien PC. Comparing two samples: extensions of the t, rank-sum, and log-rank tests. J Am Stat Assoc 1988;83:52-61.
37. O'Brien PC, Fleming TR. A multiple-testing procedure for clinical trials. Biometrics 1979;35:549-556.
38. Lublin FD, Reingold SC, for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
39. Follmann D, Wittes J, Cutler JA. The use of subjective rankings in clinical trials with an application to cardiovascular disease. Stat Med 1992;11:427-437.
40. Noseworthy J. Are placebo-controlled trials still ethical in multiple sclerosis? In: Thompson A, Polman C, Hohlfeld R, eds. A problem-oriented approach to management and treatment of multiple sclerosis. London: Martin Dunitz, 1997:177-193.